Abrogation of α-synuclein-mediated dopaminergic neurodegeneration in LRRK2-deficient rats. - Test2 - elhamkhani - TriplyDB

Abrogation of α-synuclein-mediated dopaminergic neurodegeneration in LRRK2-deficient rats.

Abrogation of α-synuclein-mediated dopaminergic neurodegeneration in LRRK2-deficient rats.

http://www.wikidata.org/entity/Q33835006

about

Phosphatases of α-synuclein, LRRK2, and tau: important players in the phosphorylation-dependent pathology of Parkinsonism Deconvoluting the complexity of autophagy and Parkinson's disease for potential therapeutic purpose Insights into Neuroinflammation in Parkinson's Disease: From Biomarkers to Anti-Inflammatory Based Therapies Oxidative stress and Parkinson's disease The complex relationships between microglia, alpha-synuclein, and LRRK2 in Parkinson's disease Ten years and counting: moving leucine-rich repeat kinase 2 inhibitors to the clinic M1 and M2 immune activation in Parkinson's Disease: Foe and ally?Leucine-Rich Repeat Kinase 2 (LRRK2) Stimulates IL-1β-Mediated Inflammatory Signaling through Phosphorylation of RCAN1.Unique functional and structural properties of the LRRK2 protein ATP-binding pocket.A Nurr1 agonist causes neuroprotection in a Parkinson's disease lesion model primed with the toll-like receptor 3 dsRNA inflammatory stimulant poly(I:C).Leucine-rich repeat kinase 2 deficiency is protective in rhabdomyolysis-induced kidney injury.Leucine-rich Repeat Kinase 2 (LRRK2) Pharmacological Inhibition Abates α-Synuclein Gene-induced Neurodegeneration.Leucine-Rich Repeat Kinase 2 Influences Fate Decision of Human Monocytes Differentiated from Induced Pluripotent Stem Cells LRRK2 and ubiquitination: implications for kinase inhibitor therapy Leucine-rich repeat kinase 2 (LRRK2) regulates α-synuclein clearance in microglia.LRRK2 mutations and neurotoxicant susceptibility G2019S-LRRK2 Expression Augments α-Synuclein Sequestration into Inclusions in Neurons.The function of orthologues of the human Parkinson's disease gene LRRK2 across species: implications for disease modelling in preclinical research.LRRK2 pathobiology in Parkinson's disease.Targeting α-synuclein as a therapeutic strategy for Parkinson's disease.Genes associated with Parkinson's disease: regulation of autophagy and beyond.How can rAAV-α-synuclein and the fibril α-synuclein models advance our understanding of Parkinson's disease?Microglial phenotypes in Parkinson's disease and animal models of the disease.Role of the JAK/STAT signaling pathway in regulation of innate immunity in neuroinflammatory diseases.Mechanisms of LRRK2-dependent neurodegeneration: role of enzymatic activity and protein aggregation.LRRK2 and the Immune System.Models of LRRK2-Associated Parkinson's Disease.Targeting Microglial Activation States as a Therapeutic Avenue in Parkinson's Disease.LRRK2 modulates microglial activity through regulation of chemokine (C-X3-C) receptor 1 -mediated signalling pathways.Inhibition of the JAK/STAT Pathway Protects Against α-Synuclein-Induced Neuroinflammation and Dopaminergic Neurodegeneration.Pharmacological LRRK2 kinase inhibition induces LRRK2 protein destabilization and proteasomal degradation The G2019S LRRK2 mutation increases myeloid cell chemotactic responses and enhances LRRK2 binding to actin-regulatory proteins.Neurodevelopmental Malformations of the Cerebellar Vermis in Genetically Engineered Rats.LRRK2 Antisense Oligonucleotides Ameliorate α-Synuclein Inclusion Formation in a Parkinson's Disease Mouse Model.LRRK2 dephosphorylation increases its ubiquitination.Leucine-rich repeat kinase 2 positively regulates inflammation and down-regulates NF-κB p50 signaling in cultured microglia cells.Licochalcone A Prevents the Loss of Dopaminergic Neurons by Inhibiting Microglial Activation in Lipopolysaccharide (LPS)-Induced Parkinson's Disease Models.MicroRNAs and Target Genes As Biomarkers for the Diagnosis of Early Onset of Parkinson Disease.Achieving neuroprotection with LRRK2 kinase inhibitors in Parkinson disease.Mechanisms of Mutant LRRK2 Neurodegeneration.

P2860

Q21131229-461F60E8-3CE1-4B0B-A64C-093B5537CC16 Q26785491-C0BC52F7-6163-47A0-A37B-2A9AF1AAB8AA Q26795984-A4075B1F-BF2C-45BD-8AB7-09C2717C6086 Q26798897-86A4EF9D-4CE0-47D5-AC8A-794E004ED2E7 Q26853537-B0015127-3004-423B-8B3B-0E987D1A5CD2 Q27007413-FA7C6557-CF3D-48DC-B2D1-1443E5B59963 Q27024667-D5B96BAA-6C49-4AE7-ADAE-CC8650FFB5EC Q33659068-665A58CD-1430-485A-8060-E7527BE536A6 Q34552787-63B9A38A-BBFE-480F-8CBA-F7426781BA19 Q35224798-5D69B4FE-9E61-4A00-9F1C-FABCBC4FA91D Q35766417-7A760578-D290-4E44-A638-9EF146B879CC Q35925767-32A50BEF-1834-4FB8-A9D2-9BE16C49B21F Q36182364-97E788FA-FDBB-4F0D-8110-DA9165242495 Q36185165-BFA832B9-119C-4E39-8156-CC8CB6AFF834 Q36208453-B93514FF-79F3-467F-B1A5-E54B5239BA3F Q37071013-7EC9C380-01BC-4703-88D0-3E590A4BF6A3 Q37096048-75807AF8-511C-45F9-A3F9-9C5C43875436 Q37513500-C925E46A-BA0D-4CCC-8900-B33459965EB4 Q38253871-8046DBCF-5C44-456E-99FD-B69DF49E75B8 Q38541943-2845E430-5F8A-4E06-8C49-BB4C1F21E9C5 Q38557027-D275E4FD-A3E2-4330-AF04-637A7BF1CD68 Q38790881-C68BFC26-D3C7-412E-A281-656F7A4BF6F1 Q38815779-48799858-3769-4728-BBE8-B48DC3233D77 Q38974101-7764F616-7F72-48B8-8EBA-8C2269C0373F Q39137358-1B3A4B39-28A7-4E42-A670-0E362F5AC2BD Q39206438-05ED81F9-55C9-4AE6-9DD6-AF6C365A079E Q39206443-29DD58BF-B1AB-4063-9731-8666E0A8466C Q39392775-DC73BB01-1FA4-49D9-B30D-BB986B8B4A07 Q39732847-2035049D-651D-485D-B61F-E9DA005CF2E3 Q40768273-C85EF59B-D9B7-410E-AEA1-B091DDBAFB33 Q41163700-4C46BF4E-69EA-4278-ACD3-D62E8F3E1128 Q41374126-00437AB4-E112-4BAF-8C12-B5484D5256A8 Q41380885-9E2DF7AB-341B-420B-A2B4-CB5F96CCF675 Q41539639-8F100AA0-FE97-45DD-A0D9-07F660DE08A0 Q41785779-AFA7C596-602C-44DA-9106-DC4D2DF89B01 Q43137963-95EFA1FE-CD12-4DFC-9769-925F6893AA8B Q47094847-6CA3FE1D-EDC8-4267-A961-04386E5866A1 Q47102033-D06FF40B-EC60-463A-8BF9-C92A7828DCA8 Q48003270-7AECF42F-8A1C-4E5C-A9C3-99FA8C0B5850 Q48239635-2BAB9E0F-7609-4915-8195-E169A2AA0EC3

P2860

Abrogation of α-synuclein-mediated dopaminergic neurodegeneration in LRRK2-deficient rats.

http://www.wikidata.org/entity/Q33835006

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Abrogation of α-synuclein-medi ...... ation in LRRK2-deficient rats.

@ast

Abrogation of α-synuclein-medi ...... ation in LRRK2-deficient rats.

@en

type

label

Abrogation of α-synuclein-medi ...... ation in LRRK2-deficient rats.

@ast

Abrogation of α-synuclein-medi ...... ation in LRRK2-deficient rats.

@en

prefLabel

Abrogation of α-synuclein-medi ...... ation in LRRK2-deficient rats.

@ast

Abrogation of α-synuclein-medi ...... ation in LRRK2-deficient rats.

@en

P1433

Q33835006-21BD1D98-6F14-467D-9EC7-4A8DE178F2B1

P1476

Q33835006-46092162-6ED3-4563-A81D-0C83EA83BFA6

P2093

Q33835006-5E5D611D-ACA4-4F9A-BF4C-2E2DEAC5D5A3

Q33835006-A6AB909B-6FC5-487E-98A4-9F65FA44808A

Q33835006-E19A9AE6-8D2A-4E96-9B8E-5A3B58362B6E

P2860

Q33835006-033A31A0-F322-4D44-A95A-435BB61C1444

Q33835006-0E4F3F58-F02F-46CD-BC59-D1CA1DBC3F44

Q33835006-1969926A-F4B9-4308-8F89-84F872ABF26D

Q33835006-248F6DC1-A2F9-4056-9960-E0E3339DCD2E

Q33835006-28D8F36E-5C6E-48C8-9332-C007A2A96558

Q33835006-32D2073F-02F5-42EB-86CF-6AFBAE37745F

Q33835006-3849A688-991A-47ED-8C77-B4B6A05F6BD2

Q33835006-3ADC0219-53E2-4A16-84C7-CE49C0E6DC89

Q33835006-572A4047-4425-4FD7-B55E-43928F6C94D9

Q33835006-581F777D-8D68-42B1-AD0F-F0464ED7EBEA

P304

Q33835006-6B1DA5AC-1E38-4AB3-84E9-0F85B6D392B2

P31

Q33835006-A78110FC-5521-4516-AED7-8483AD21ABEA

P356

Q33835006-299EF4CC-A57D-44FE-98B1-5DBD56F6712F

P407

Q33835006-3050A18A-C2CD-4FA2-BF44-7D46812908A3

P433

Q33835006-41263BCF-4B8C-4003-90DC-CD0F35352989

P478

Q33835006-AD7D37B2-013E-4BA3-B8FA-CB55914B4B42

P50

Q33835006-2C539986-806A-48C5-88ED-3F9B0BC2D82D

Q33835006-82FE3E5D-DCAB-4B6F-B03A-FAB0A0CB6FD6

P577

Q33835006-AB2DC0E2-4F22-43DD-9531-23D850A76E59

P5875

Q33835006-478957AB-C55C-466C-A8DD-EBAAE890D982

P698

Q33835006-AC5B9099-0E06-4100-9EC5-8610EBA161E8

P921

Q33835006-8FB074D9-732C-4B3A-9296-4BB96B6F25E6

Q33835006-E533D24B-10E2-42A8-8DAB-0AFA13338BE2

P932

Q33835006-9D1C00A4-9DC6-40D6-96C7-2982701B1D89

P356

PNAS.1403215111

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Abrogation of α-synuclein-medi ...... ation in LRRK2-deficient rats.

@en

P2093

Jonathan P Blackburn

http://www.w3.org/2001/XMLSchema#string

João P L Daher

http://www.w3.org/2001/XMLSchema#string

Laura A Volpicelli-Daley

http://www.w3.org/2001/XMLSchema#string

P2860

A two-stage meta-analysis identifies several new loci for Parkinson's disease

Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies

High LRRK2 levels fail to induce or exacerbate neuronal alpha-synucleinopathy in mouse brain

Regulation of LRRK2 expression points to a functional role in human monocyte maturation

Genomewide association study of leprosy

Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice

Neurodegenerative phenotypes in an A53T α-synuclein transgenic mouse model are independent of LRRK2.

Microglia acquire distinct activation profiles depending on the degree of alpha-synuclein neuropathology in a rAAV based model of Parkinson's disease.

Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein.

Association of variants at 1q32 and STAT3 with ankylosing spondylitis suggests genetic overlap with Crohn's disease

P304

9289-9294

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.1403215111

http://www.w3.org/2001/XMLSchema#string

P407

P433

25

http://www.w3.org/2001/XMLSchema#string

P478

111

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-06-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

263097023

http://www.w3.org/2001/XMLSchema#string

P698

24927544

http://www.w3.org/2001/XMLSchema#string

P921

P932

4078806

http://www.w3.org/2001/XMLSchema#string